Understanding how patients and families react to Alzheimer’s disease biomarker results
Official title: Patient and Family Member Reactions to Biomarker-Informed ADRD Diagnoses
Funded at University of Pittsburgh at Pittsburgh · NIH-10589205 · Data updated 2026-11-12
This study is looking at how patients and their families feel when they get test results about Alzheimer’s disease, especially focusing on the emotional effects like anxiety and depression, and it includes a diverse group of people to better understand their experiences.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | March 1, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2023 |
| Award (this year) | $2,112,023 |
| NIH project number | 1RF1AG080591-01 |
| Project ID | NIH-10589205 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include Medicare beneficiaries, especially those who are Black or Hispanic, who are undergoing evaluation for cognitive disorders.
✕Less likely to help
Patients who are not Medicare beneficiaries or those who do not have cognitive disorders may not receive any benefit from this research.
What this research studies
This research investigates the reactions of patients and their family members to receiving biomarker results related to Alzheimer’s disease (AD). It aims to explore the psychological impacts, including anxiety and depression, of disclosing these results, particularly in diverse populations that have been historically underrepresented in such studies. By enrolling 7,000 Medicare beneficiaries, including a significant number of Black and Hispanic participants, the study seeks to provide a comprehensive understanding of the burdens and benefits associated with AD biomarker testing in real-world settings. The findings will help inform clinical practices and patient care delivery.
Why it matters
Potential benefit: If successful, this research could lead to improved patient care and support for individuals diagnosed with cognitive disorders, particularly in understanding the implications of biomarker testing.
How similar studies have gone: Previous research has shown that disclosing AD biomarker results does not lead to increased anxiety or depression in selected populations, but this study aims to expand understanding to more diverse groups.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Lingler, Jennifer Hagerty — University of Pittsburgh at Pittsburgh
- Study coordinator: Lingler, Jennifer Hagerty
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.